Objective: A rise in circulating dehydroepiandrosterone sulfate (DHEAS) concentration occurs during the menopausal transition (MT) that is ovarian stage related but not age related. The objective of this study was to determine the source of the rise in circulating DHEAS.
P revious and recent reports reveal a positive inflection in circulating dehydroepiandrosterone sulfate (DHEAS) that occurs during the menopausal transition (MT) of most women. 1, 2 This rise in DHEAS is detectable in annual samples of 85% of middle-aged women and is associated with changes in ovarian status, with the positive slope beginning in the early perimenopause and continuing until the early postmenopause, ultimately declining to premenopausal levels in the late postmenopause.
The positive inflection of DHEAS is common across five ethnic groups, that is, white, African American, Hispanic, Chinese, and Japanese, 1, 2 and has the potential to significantly affect the circulating estrogen-to-androgen balance. 2 The peripheral conversion of DHEAS to more bioactive steroid hormones contributes to an individual woman's endocrine status and may determine her symptoms and health. Although potentially important, neither the source nor the mechanism by which this rise in DHEAS is propagated is known. The necessity in understanding the dynamics of DHEAS changes in perimenopausal women is underscored by the accumulating data on the increasing clinical use of dehydroepiandrosterone (DHEA) for the treatment of postmenopausal vaginal atrophy 3 and premature ovarian failure. 4 Both the adrenal glands and the ovaries have the capacity to synthesize and secrete DHEA, which can then be sulfated by the liver. Thus, the increased production from either or both of these steroidogenic organs could contribute to the shift in circulating DHEAS that is observed during the MT. 5, 6 An increase in ovarian DHEA can be induced by the administration of follicle-stimulating hormone (FSH) in women with polycystic ovary syndrome, 7 and an ovarian-to-peripheral vein gradient of DHEA is observed in postmenopausal women, 6 indicating that the increase in circulating DHEAS observed during the MT could be attributable to increased steroid production by the ovaries, the adrenals, or both.
Investigating the endocrine profile of women who had undergone surgical menopause may therefore provide insight into the source of the increase in circulating DHEAS. If women who had undergone bilateral salpingo-oophorectomy (BSO) during the early perimenopause did not exhibit a rise in DHEAS during the subsequent MT, then this would indicate that the ovaries were primarily responsible for the increase in DHEAS production that is observed during the MT. However, if women who had undergone BSO before the late perimenopause continued to exhibit robust increases in DHEAS during the remainder of the MT, in a manner similar to the rise in DHEAS observed in women undergoing natural menopause, then the source of the rise in DHEAS would be attributable primarily to the adrenals.
The purposes of this investigation were to identify and characterize participants in the Study of Women's Health Across the Nation (SWAN) who had undergone BSO during the premenopause and early perimenopause and were followed with subsequent annual blood collections. Using these annual serum samples, the mean DHEAS profiles of these women were compared with the mean DHEAS profiles of women undergoing natural menopause during the same MT stages. The result of this comparison was used to clarify whether the presence of the ovaries is necessary for the inflection and rise in DHEAS in the MT transition.
METHODS

Participants
In a previous report, 2 within-woman changes in annual circulating DHEAS concentrations occurring during natural (nonsurgical) MTs were assessed, omitting women who underwent simple hysterectomy or BSO and women who did not reach late perimenopause. This study compares women with intact ovaries with those who underwent BSO after a premenopausal or early perimenopausal annual visit. Of the 81 participants meeting this criterion, DHEAS measurements postsurgery were concurrent with hormone therapy (HT) for 38 women, and another 23 women used HT at two or more consecutive visits postsurgery, leaving 20 women with at least one HT-free DHEAS measurement postsurgery available for these analyses. This relatively small number of well-defined participants results from the requirements that a woman be premenopausal or early perimenopausal at the visit preceding the BSO (of 74 women who underwent other BSOs, 24 had already had a simple hysterectomy, 30 were late perimenopausal or postmenopausal, and 20 were using HT at the visit before the surgical operation) and have HT-free DHEAS measurements before the surgical operation. For comparison, we also included data from participants with intact ovaries. Of the 3,221 women who did not undergo BSO during premenopause/early perimenopause, 184 underwent a hysterectomy or a BSO during HT use or after early perimenopause, 1,870 had no DHEAS measurements during late perimenopause, and 8 had missing outcome or covariate data, yielding a sample of 1,159 women with intact ovaries.
Assays
An automated ACS:180-based chemiluminescent assay was developed using Bayer Diagnostics ACS:180 to determine the levels of DHEAS in human serum. This chemiluminescent immunoassay involves the competitive binding of a dimethyl acridinium esterYlabeled DHEAS derivative to a rabbit anti-DHEAS antibody. The solid phase is goat antirabbit IgG conjugated to superparamagnetic particles. Ten microliters of unextracted serum is required for the assay in addition to sufficient dead volume for aspiration and repeat analysis. The assay range is 1.52 to 1,020 Kg/dL and the assay is standardized against DHEAS obtained from Steraloids. The detection level of this assay is approximately 1.9 Kg/dL. Closely related steroids (danazol, cholesterol, pregnenolone, 17>-hydroxyprogesterone, corticosterone, 17>-estradiol, 17Aestradiol, testosterone, estriol, 11-deoxycortisol, norethindrone, estrone, aldosterone, estradiol glucuronide, and cortisol) show little cross-reactivity in the assay, indicating high specificity. The assay demonstrates acceptable parallelism of diluted serum samples and recovery of added exogenous hormone. DHEA cross-reacts 192%, but the low levels of serum DHEA render this inconsequential. The expected values are 150 to 500 Kg/dL for normally cycling women and 10 to 350 Kg/dL for postmenopausal women. The intra-assay coefficient of variation is 8.02% (n = 261), and the interassay coefficient of variation is 11.34% (53.32 Kg/dL, n = 37) and 9.74% (250.21 Kg/dL, n = 37).
Analysis plan
The outcome variable, DHEAS, was natural log transformed to normalize its skewed distribution. Independent variables included baseline and concurrent menopause status according to the Stages of Reproductive Aging Workshop Convention, 8 categorized as follows: premenopausal or early perimenopausal (G3 mo amenorrhea), late perimenopausal or early postmenopausal (93 mo of amenorrhea but within 2 y of final menstrual period), late postmenopausal (92 y after final menstrual period), and BSO. Covariates included ethnicity, clinical site, baseline weight, baseline height, age, baseline smoking (never, current, or past), and HT use at a previous SWAN visit. Analyses included height and weight rather than body mass index (BMI) because within-woman changes in BMI are due primarily to changes in weight. 9 Observations concurrent with exogenous hormone use or within a 6-month washout period after hormone discontinuation were omitted from analyses. BSO and intact participants were compared with respect to baseline characteristics using Fisher's exact test for categorical variables and Wilcoxon's rank sum test for continuous variables. For within-woman changes in log DHEAS associated with the MT, we estimated a linear mixed model (PROC MIXED in SAS) as a function of baseline and concurrent menopause status, adjusting for the covariates listed previously. The time-varying covariates age and weight were separated into baseline value and change since baseline, to distinguish between-woman (cross-sectional) and withinwoman (longitudinal) effects.
Mean within-woman changes in log DHEAS associated with transitions from one menopause stage to another, particularly premenopause/early perimenopause to BSO and premenopause/early perimenopause to late perimenopause/early postmenopause, as well as the difference in these two withinwoman changes, were estimated from the model using appropriate contrasts. Next, we estimated woman-specific changes in log DHEAS by including random effects (ie, womanspecific estimates) for the intercept and time-varying menopause status.
RESULTS
The characteristics of the 20 BSO participants were similar to those of the participants with intact ovaries, with the exception of BMI (Table 1 ). The higher BMI in BSO women was not attributable to a disproportionate number of African American women in the BSO group, as adjustment for ethnicity had little impact on the magnitude of this difference and the difference remained statistically significant. On average, the BSO occurred 8.0 months (range, 1.3-15.3 mo) after the last presurgery annual visit. BSO date was unknown for two women who did not undergo hysterectomy, as only the date of hysterectomyVand not BSOVwas ascertained. The total number of visits of the women included in the analyses was similar for BSO (mean, 7.3 visits; range, 2-11 visits) and intact (mean, 8.0 visits; range, 2-11 visits) participants. Among BSO participants, 90% had at least two postsurgery observations included in analyses (mean, 3.4; range, 1-9).
Among the BSO women, the mean within-woman change in log DHEAS for premenopause/early perimenopause to BSO was 0.074, corresponding to a 7.69% increase in DHEAS, whereas among the women with intact ovaries, the mean within-woman change in log DHEAS for premenopause/ early perimenopause to late perimenopause/early postmenopause was 0.048, corresponding to a 4.93% increase in DHEAS. Comparing these two estimated mean changes in log DHEAS, the between-group difference was j0.026 (SE, 0.065; P = 0.69). In short, the mean within-woman increase in DHEAS from premenopause/early perimenopause to after BSO was larger than the corresponding increase from premenopause/early perimenopause to late perimenopause/ early postmenopause in the intact group, but this difference was not statistically significant, probably because of a small sample size for the BSO group.
The adjusted within-woman change pre-and post-BSO ( Fig. 1 ) was positive for 70% (n = 14) of the 20 BSO participants, compared with a positive adjusted within-woman change in DHEAS between premenopause and early perimenopause and late perimenopause/early postmenopause occurring in 85% of women with intact ovaries. 2 The range of increase for the 14 women who exhibited a rise in DHEAS after surgical operation was from 2.5 to 31.6 Kg/dL, and the decline in DHEAS for the six women who exhibited a fall in DHEAS ranged from 2.0 to 31.2 Kg/dL (Fig. 2) .
DISCUSSION
The present data demonstrate that the previously observed rise in DHEAS during the MT transition is evident even in the absence of the ovaries in 70% (14/20) of the BSO women. These data suggest strongly that the MT-associated rise in DHEAS is, in part, an adrenal phenomenon. Although the observed increases in DHEAS levels are small on an annual basis, they represent a potentially large contribution of substrate for peripheral conversion to more bioactive sex steroids when the total sex steroid milieu of the MT is considered. 10 Furthermore, these data suggest that individual differences in adrenal steroid production may be primarily responsible for individual differences in total circulating sex steroid levels during the MT and therefore contribute to the range of phenotypes that are observed at this time.
The predominant peripheral conversion products of DHEA in women are androgens and not estrogens. 11, 12 Our data therefore also suggest that the androgen-estrogen balance may be determined by adrenal function and ovarian function in the years just preceding and at menopause. The decline in ovarian function, which seems to be requisite for inducing an increase in adrenal steroid production, can be either gradual as with natural menopause or abrupt as with surgical menopause, as demonstrated here. Furthermore, once initiated, this induction is sustained for several years and continues past menopause in women with intact ovaries. It would seem, therefore, that the initial decline in ovarian function provides a trigger for an event that may include years of subsequent increased adrenal steroidogenesis.
Although these findings show that the ovaries are not required for the sustained rise in DHEAS through the MT, they do not exclude the ovaries from participating in that event. The source of circulating androgens in middle-aged women has been a contentious issue for decades, and the present study provides some clarity to that controversy. Because the circulating levels of DHEAS are maintained after menopause at levels similar to those at premenopause, 13 comparisons with earlier studies of postmenopausal women may provide useful information regarding the nature of ovarian steroid production. In one of the earliest studies, positive ovarian arteriovenous gradients for testosterone, androstenedione, and DHEA were documented in postmenopausal women and demonstrated the ability of the senescent ovary to continue to produce androgens including DHEA. 5 The premenopausal ovary contributes approximately half of the circulating testosterone and androstenedione 14 and continues to produce androgens past menopause. 5 However, there is controversy regarding the amount of androgens that the human ovary produces at different life stages. Couzinet et al 15 found the necessary steroidogenic machinery for androgen production to be missing in the ovaries of postmenopausal women with adrenal insufficiency. This is in conflict with an earlier study 16 that reported that DHEAS levels were more than twofold lower in women without ovaries versus age-matched premenopausal and postmenopausal women with intact ovaries. In contrast, DHEAS levels were similar in 610 intact and 125 BSO women in the Rancho Bernardo Study and displayed a similar decline with age. 17 These results do not support an ovarian contribution to circulating DHEAS in older women and are consistent with the observations of an absence of a change in DHEAS levels in 20 postmenopausal women during the 6 weeks after BSO. 18 The bulk of the data to date do not favor an ovarian contribution to the circulating pool of DHEAS.
There is limited but positive evidence to suggest that the human premenopausal ovary can produce significant amounts of DHEAS under specific conditions. Barnes et al 19 treated a woman with isolated FSH deficiency with FSH, followed by human chorionic gonadotropin, to show that FSH exposure resulted in the ability of the ovary to respond to a luteinizing hormone stimulation by increasing DHEA production. Similarly, Wachs et al 7 demonstrated an increase in circulating DHEA after treatment of women with polycystic ovarian syndrome with recombinant FSH. More recently, ovarian arteriovenous samples reveal a DHEA gradient several years after menopause. 6 Although all of these studies demonstrate the potential for the ovary to secrete DHEA, none of the study participants were normal, premenopausal, middle-aged women. Until there is additional evidence or a better understanding of the mechanism(s) involved, it seems reasonable to conclude that most of the increase in DHEAS observed during the MT is a result of increased adrenal steroid production.
There are at least two weaknesses in our study. Foremost is that there was no intention or experimental design to investigate adrenal function in the original SWAN design because at that time, there was no rationale to do so. In fact, DHEAS was included in SWAN as a measure of somatic aging, with the assumption that circulating levels would continuously decline with chronological age and therefore provide a between-woman, independent reference for ovarian aging, which was in line with conventional thinking at that time. Second is the absence of any measure to determine if either the clearance or the sulfation of DHEA changes in middleaged women. Fortunately, there is at least one study that indicates that this is not the case. 20 
CONCLUSIONS
In summary, we have demonstrated that most middle-aged women who are undergoing the MT demonstrate a transient increase in circulating DHEAS level that seems to be independent of ovarian function and evident in a similar proportion of women, whether their ovaries had been surgically removed. These findings highlight the importance of acknowledging adrenal androgen production as a potentially important source of circulating sex steroids in perimenopausal and postmenopausal women.
